Roche Pharma CEO Teresa Graham outlined the company’s priorities for the coming years at the J.P. Morgan Healthcare Conference 2026, emphasizing maximising the on-market portfolio to sustain growth through 2028, delivering key launches in 2026, and preparing entry into new disease areas including Alzheimer’s and obesity with a broad, diversified pipeline of new molecular entities (NMEs).
Roche is on track to meet its 2025 financial target, reporting year-to-date sales of CHF 35.6 billion ($44.5 billion) by September 2025, with CHF 18 billion ($22.5 billion) from its oncology and haematology portfolio. The marketed portfolio includes 17 blockbuster drugs and continued growth across multiple franchises.
Oncology and haematology strengths cited by Graham include breast cancer (Phesgo, Kadcyla, Perjeta, Itovebi), solid tumours (Tecentriq), diffuse large B‑cell lymphoma (Polivy, Columvi/Lunsumio), and haemophilia A (Hemlibra). Roche said about 60% of its R&D pipeline and total drug sales are conducted through partnerships and acquisitions. The company expects filings for up to three NMEs in 2026.
Giredestrant, a next‑generation selective oestrogen receptor degrader (SERD), is a focal point in Roche’s oncology pipeline. It is in Phase III for early and metastatic breast cancer, with giredestrant plus everolimus in pre‑registration with the US Food and Drug Administration and an expected European Medicines Agency filing in 2026. Roche positions giredestrant as a potential replacement for standard endocrine therapy in ER‑positive breast cancer and as synergistic with PI3K/AKT/mTOR inhibitors.
Roche’s small‑molecule portfolio complements giredestrant and targets key signalling nodes, including the PI3K inhibitor Itovebi, the CDK4/2 inhibitor GDC‑4198 aimed at overcoming CDK4/6 inhibitor resistance, and the brain‑penetrant HER2 tyrosine kinase inhibitor ZN‑1041. Key Phase III readouts expected in 2026 include giredestrant plus palbociblib in first‑line ER+/HER2‑ metastatic breast cancer (persevERA), Itovebi with fulvestrant in post‑CDKi HR+ metastatic breast cancer (INAVO121), and Itovebi with Phesgo for PIK3CA‑mutant HER2+ metastatic breast cancer (INAVO122).
Analyst consensus forecasts from GlobalData project giredestrant could reach $1.7 billion in sales by 2031. The oral SERD field is competitive: AstraZeneca’s camizestrant is in pre‑registration with the FDA and forecast at $1.8 billion in 2031, while palazestrant (Olema Pharmaceuticals) is in Phase III and projected at $1.3 billion. Roche says clinical differentiation and in‑house combinations will be critical to secure leadership in the evolving HER2‑/HR+ space.
Other regulatory milestones and readouts expected in 2026 include potential US approval of the Lunsumio plus Polivy combination in DLBCL, Phase III results for the KRAS G12C inhibitor divarasib in non‑small cell lung cancer (KRASCENDO 1), and data supporting Lunsumio’s label expansion into earlier lines for follicular lymphoma (CELESTIMO).
In haemophilia A, Roche highlighted NXT007, a bispecific antibody licensed from Chugai Pharmaceutical that targets factors IX and X and is in Phase II. GlobalData forecasts NXT007 sales of $760 million in 2031.
Graham expressed confidence that Roche’s marketed products will drive growth through 2028, supported by upcoming 2026 launches and anticipated positive Phase III readouts. The company also aims to develop potentially first‑in‑class and best‑in‑class medicines across oncology, haematology, immunology, neurology, and ophthalmology, and to become a top‑three player in obesity with five NMEs planned for 2026 focused on further iterations of the incretin pathway and novel mechanisms of action.
Leave a Reply